X


See our webpage about the GA-map® product platform

 

Visit page
Skip to content
Genetic Analysis
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Subsequent Offering 2025
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Mailing List
  • Contact us
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Subsequent Offering 2025
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Mailing List
  • Contact us

Ronny Hermansen

Genetic Analysis AS announces milestone in the IBD diagnostic test development project – completion of biomarker panel for GA-map® IBD Precision Dx

2025-11-17

Genetic Analysis attends the Biomarkers & Precision Medicine congress in London

2025-09-262025-09-26

Genetic Analysis AS launches the GA-map® MHI GutHealth reagent kit

2025-09-262025-09-24

Publication of Half-year report 2025

2025-08-272025-08-27

Genetic Analysis AS and Pangea Laboratory LLC announces the launch of GA-map® MHI GutHealth in the USA

2025-08-042025-07-29

Genetic Analysis subsequent offering to existing shareholders has now been registered with the Norwegian Register of Business Enterprises

2025-06-302025-06-27

Genetic Analysis announces final outcome of the subsequent offering to existing shareholders

2025-06-302025-06-18

Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises

2025-06-18

Genetic Analysis announces preliminary outcome of the subsequent offering to existing shareholders

2025-06-182025-06-16

Genetic Analysis AS: Mandatory notification of trade

2025-06-182025-06-12
Post navigation
Older posts
Page1 Page2 Page3 Next →

Genetic Analysis AS is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Contact

Phone: +47 48 32 16 10
E-mail: info@genetic-analysis.com
Address: Genetic Analysis AS, Ulvenveien 80B
0581 Oslo, Norway

Open Google Maps
Connect

LinkedIn

Facebook

Twitter

Navigate

Contact Us

Terms of Use

Privacy Policy

© 2023 Genetic Analysis

  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Subsequent Offering 2025
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Mailing List
  • Contact us